Thor Medical ASA (FRA:8NN) Valuation Rank


FRA:8NN Thor Medical ASA FRA:8NN
21 GF Score
Price €0.39
! 2 Warning Signs
View Full Analysis

What is Thor Medical ASA Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Thor Medical ASA Valuation Rank Related Terms

FRA:8NN
21GF Score
Thor Medical ASA FRA:8NN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thor Medical ASA Business Description

Other Exchanges TRMED:Norway0R6Y:UK
Address Drammensveien 167, Oslo, NOR, 0277
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
21GF Score

Get the complete analysis for FRA:8NN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.39
Price